Table 4.
Differences of CD4+ and CD8+ lymphocytes T with expression of CD25+, CD45RO+, HLA-DR+ or CD38+ between patients: with positive COVID-19 test—group A, control group (HC)—group B and group with other virus infections with negative COVID-19 test—group C. Data expressed as median of percentage or geometric mean fluorescence (GMF) intensity (Q1–Q3).
| Lymphocyte Subset (%) [Median (Q1–Q3)] |
A. COVID-1(+) n = 20 |
B. HC n = 20 |
C. COVID-19(−) Viruses n = 20 |
* p < 0.05 A-B-C Anova |
* p < 0.05 in Group Post Hoc |
|---|---|---|---|---|---|
| CD4+ subpopulation: (% of CD4+ cells) | |||||
| CD4+ CD25 % | 3.0 (2.0–6.5) | 19.8 (13.2–29.1) | 24.1 (20.3–33.2) | * 0.0000 | * A-C * A-B |
| CD4+ CD25 GMF | 108.0 (96.0–135.0) | 304.5 (229.5–352.0) | 290.0 (251.0–366.5) | * 0.0120 | * A-C * A-B |
| CD4+ CD45RO % | 65.7 (52.2–75.3) | 73.2 (61.3–82.3) | 73.3 (61.4–77.0) | - | - |
| CD4+ CD45RO GMF | 2437.5 (1647.0–4373.0) | 4807.5 (3194.5–7098.5) | 5280.5 (3651.0–7793.5) | * 0.0129 | * A-C * A-B |
| CD4+ HLA-DR+ % | 6.1(4.2–12.9) | 10.7 (8.3–14.5) | 8.7 (7.0–31.0) | - | - |
| CD4+ HLA-DR+ GMF | 118.0 (105.0–158.0) | 137.5 (124.5–159.0) | 148.5 (122.5–386.0) | - | - |
| CD4+ CD38+ % | 11.0 (9.0–13.5) | 18.0 (11.9–27.4) | 23.0 (16.5–53.1) | * 0.0050 | * A-C |
| CD4+ CD38+ GMF | 313.0 (262.0–390.0) | 232.5 (185.5–286.0) | 317.0 (216.5–865.0) | - | - |
| CD8+ subpopulation: (% of CD8+ cells) | |||||
| CD8+ CD25+ % | 0.2 (0.0–1.2) | 2.5 (0.9–4.5) | 3.4 (1.4–6.6) | * 0.0009 | * A-C * A-B |
| CD8+ CD25+ GMF | 80.5 (63.0–101.0) | 121.0 (112.0–138.0) | 127.5 (119.0–144.5) | * 0.0001 | * A-C * A-B |
| CD8+ CD45RO+ % | 30.0 (20.8–35.9) | 65.0 (55.9–71.5) | 51.9 (42.9–66.4) | * 0.0001 | * A-C * A-B |
| CD8+ CD45RO+ GMF | 796.0 (571.0–1293.0) | 2683.5 (1922.0–3735.5) | 2136.0 (1313.5–3061) | * 0.0002 | * A-C * A-B |
| CD8+ HLA-DR+ % | 22.5 (14.5–31.3) | 31.5 (23.3–34.3) | 28.2 (18.6–76.3) | - | - |
| CD8+ HLA-DR+ GMF | 200.5 (165.0–307.0) | 262.5 (206.5–298.0) | 246.0 (183.0–3613.5) | - | - |
| CD8+ CD38+ % | 23.3 (15.1–49.5) | 6.3 (4.3–11.0) | 19.6 (5.4–80.0) | * 0.0222 | * A-B |
| CD8+ CD38+ GMF | 349.0 (233.0–589.0) | 137.0 (127.0–177.0) | 229.0 (131.5–2000.5) | * 0.0050 | * A-B |
Abbreviations: GMF, geometric mean fluorescence; HC, healthy control; RE-LYMP, reactive lymphocytes, * p < 0.05 statistically significant.